28 related articles for article (PubMed ID: 36917917)
1. Advances in molecular agents targeting toll-like receptor 4 signaling pathways for potential treatment of sepsis.
Zheng Y; Gao Y; Zhu W; Bai XG; Qi J
Eur J Med Chem; 2024 Mar; 268():116300. PubMed ID: 38452729
[TBL] [Abstract][Full Text] [Related]
2. NaAsO
Li S; Zhang J; Ma M; Zhang M; Li L; Chen W; Li S
Biol Trace Elem Res; 2024 Jan; 202(1):258-267. PubMed ID: 36988786
[TBL] [Abstract][Full Text] [Related]
3. Total Flavonoids of
Huang S; Lin L; Wang S; Ding W; Zhang C; Shaukat A; Xu B; Yue K; Zhang C; Liu F
Antioxidants (Basel); 2023 Mar; 12(4):. PubMed ID: 37107194
[TBL] [Abstract][Full Text] [Related]
4. Aflatoxin B1 induces liver injury by disturbing gut microbiota-bile acid-FXR axis in mice.
Liu Y; Li J; Kang W; Liu S; Liu J; Shi M; Wang Y; Liu X; Chen X; Huang K
Food Chem Toxicol; 2023 Jun; 176():113751. PubMed ID: 37030333
[TBL] [Abstract][Full Text] [Related]
5. Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis.
Shirai Y; Yoshiji H; Noguchi R; Kaji K; Aihara Y; Douhara A; Moriya K; Namisaki T; Kawaratani H; Fukui H
J Gastroenterol Hepatol; 2013 Apr; 28(4):723-30. PubMed ID: 23301938
[TBL] [Abstract][Full Text] [Related]
6. Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice.
Li L; Chen L; Hu L; Liu Y; Sun HY; Tang J; Hou YJ; Chang YX; Tu QQ; Feng GS; Shen F; Wu MC; Wang HY
Hepatology; 2011 Nov; 54(5):1620-30. PubMed ID: 21809356
[TBL] [Abstract][Full Text] [Related]
7. TLR3/4 signaling is mediated via the NFκB-CXCR4/7 pathway in human alcoholic hepatitis and non-alcoholic steatohepatitis which formed Mallory-Denk bodies.
Liu H; Li J; Tillman B; Morgan TR; French BA; French SW
Exp Mol Pathol; 2014 Oct; 97(2):234-40. PubMed ID: 24997224
[TBL] [Abstract][Full Text] [Related]
8. ANTI-INFLAMMATORY ACTIVITY OF PLATYCODIN D ON ALCOHOL-INDUCED FATTY LIVER RATS VIA TLR4-MYD88-NF-κB SIGNAL PATH.
Wu JT; Yang GW; Qi CH; Zhou L; Hu JG; Wang MS
Afr J Tradit Complement Altern Med; 2016; 13(4):176-183. PubMed ID: 28852734
[TBL] [Abstract][Full Text] [Related]
9. Effects of the TLR4/Myd88/NF-κB Signaling Pathway on NLRP3 Inflammasome in Coronary Microembolization-Induced Myocardial Injury.
Su Q; Li L; Sun Y; Yang H; Ye Z; Zhao J
Cell Physiol Biochem; 2018; 47(4):1497-1508. PubMed ID: 29940584
[TBL] [Abstract][Full Text] [Related]
10. Role of targeting TLR4 signaling axis in liver-related diseases.
Tang YL; Zhu L; Tao Y; Lu W; Cheng H
Pathol Res Pract; 2023 Apr; 244():154410. PubMed ID: 36917917
[TBL] [Abstract][Full Text] [Related]
11. Alleviation of non-alcoholic fatty liver disease by Huazhi Fugan Granules is associated with suppression of TLR4/NF-κB signaling pathway.
Ye M; Tang Y; He J; Yang Y; Cao X; Kou S; Wang L; Sheng L; Xue J
Clin Investig Arterioscler; 2021; 33(5):257-266. PubMed ID: 33810882
[TBL] [Abstract][Full Text] [Related]
12. Targeting the TLR4 signaling pathway by polyphenols: A novel therapeutic strategy for neuroinflammation.
Rahimifard M; Maqbool F; Moeini-Nodeh S; Niaz K; Abdollahi M; Braidy N; Nabavi SM; Nabavi SF
Ageing Res Rev; 2017 Jul; 36():11-19. PubMed ID: 28235660
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
